Whibley Daniel, Dean Linda E, Basu Neil
Epidemiology Group, Institute of Applied Health Sciences, University of Aberdeen, School of Medicine and Dentistry, Foresterhill, Aberdeen, Scotland AB25 2ZD UK.
Curr Treatm Opt Rheumatol. 2016;2(4):312-320. doi: 10.1007/s40674-016-0056-5. Epub 2016 Oct 13.
Specialists' views of fibromyalgia (FM) are typically colored by their experiences of the selected, complex cases that they are regularly called to evaluate. At a population level, it is crucial to recognize that education which promotes patient empowerment and non-pharmacological interventions which support self-management are very effective. The temptation, for both physician and patient, to first reach for pharmacological interventions should be resisted until such holistic approaches are explored. In particular, a strong evidence base supports graded exercise and cognitive behavioral therapies, but such treatments must be intelligently "prescribed." As reflected by the recent ACR criteria, FM is a highly heterogeneous disorder and is not simply a disorder of pain. For some patients, co-occurring symptoms, such as fatigue, can be equally as impactful and so management strategies should be sufficiently versatile to target those dimensions which are considered priorities at the level of the individual patient. In those patients who do require pharmacological support, patients should not be led to expect significant gains in isolation. The importance of self-management requires emphasis at each and every tier of management. It is true that advances in our understanding of neurobiology have greatly informed the selection of adjunctive drug classes which may provide benefit (as well as those which do not-as is the case of opioids). However, further unpicking of pathogenesis is still required if the FM landscape is to move further towards drug-led management.
专家对纤维肌痛(FM)的看法通常受其在日常评估中所接触的特定复杂病例的影响。在总体层面上,必须认识到促进患者自主的教育以及支持自我管理的非药物干预措施非常有效。在探索这些整体方法之前,医生和患者都应抵制首先采用药物干预的诱惑。特别是,有强有力的证据支持分级运动和认知行为疗法,但此类治疗必须明智地“开出处方”。正如最近美国风湿病学会(ACR)的标准所反映的那样,FM是一种高度异质性疾病,而不仅仅是疼痛性疾病。对一些患者来说,诸如疲劳等并发症状可能同样具有影响力,因此管理策略应足够灵活,以针对个体患者层面被视为优先事项的那些方面。在那些确实需要药物支持的患者中,不应让患者期望仅靠药物就能有显著改善。在管理的每一个层面都需要强调自我管理的重要性。诚然,我们对神经生物学理解的进展极大地为辅助药物类别的选择提供了依据,这些药物可能带来益处(以及那些没有益处的药物——比如阿片类药物)。然而,如果FM领域要进一步走向以药物为主导的管理,仍需要进一步深入研究发病机制。